Induced Abortion Clinical Trial
Official title:
Comparison of Twq Different Regimen of Vaginal Misoprostol for Nid Trimester MTP
The hypothesis of the study is that the induction abortion interval time will be significantly shorter in the group receiving vaginal misoprostol every six hours in comparison to the group who are receiving vaginal misoprostol every twelve hours.
Objectives:
Misoprostol, a prostaglandin analogue, is principally used to prevent peptic ulcer disease
induced by nonsteroidal anti-inflammatory agents .It has been shown to induce second
trimester abortion .However , the optimal regimen has not been determined .Studies have used
doses ranging 200- 800 microgram misoprostol at interval ranging from 3-12 hours.1,2,3,4,5
In our previous study we have compared intravaginal misoprostol with extra amniotic
ethacridine lactate for second trimester MTP.6 In this study we have observed that
misoprostol is highly effective( success rate 95%) for second trimester MTP with minimal
side effects .& intravaginal misoprostol results in significantly shorter induction abortion
interval in comparison to extra amniotic ethacridine lactate .Induction abortion interval in
this study for misoprostol was 15.5 hours and the dosage of misoprostol was 400 microgram
vaginally every 12 hours with a maximum of 4 doses .Success rate and induction abortion
interval are the major factors of clinical importance for second trimester MTP . Our aim is
to establish a dosage schedule of misoprostol which will result in high success rate in mid
trimester MTP with further shortening of induction abortion interval Our study hypothesis is
that using 400 microgram of vaginal misoprostol at six hour interval will result in
significant shortening of induction abortion interval in comparison to 400 microgram vaginal
misoprostol at 12 hour interval.
Methods - A prospective randomized comparative clinical trial will be conducted over 200
women.
Women attending the hospital for mid trimester MTP i.e. 12-20 weeks of pregnancy will be
taken up for the study. Gestational age will be determined from LMP & per abdominal
findings. Ultrasonography will be done in selected women where clinical finding is
unreliable . All women will be examined for vital parameters and routine hematological and
urine examination will be done. Randomization will be done using a table of random numbers
.A written consent for inclusion in the study will be taken from all patients who will be
included in the study.
In one group women will receive 400 microgram vaginal misoprostol tablet at interval of 12
hours with a maximum of four doses.
In other group women will receive 400 microgram vaginal misoprostol tablet at an interval of
6 hours with a maximum of four doses.
Failure of procedure in both groups will be defined as failed expulsion of fetus at 48 hours
or as the occurrence of systemic adverse signs and symptoms severe enough to preclude the
use of additional drugs.
The patient's vital signs will be monitored every four hours and the occurrence of signs and
symptoms, such as fever, pain, vomiting, and diarrhea will be recorded. After expulsion of
the fetus and placenta, check curettage will be done in every case. Completeness of abortion
will be defined as expulsion of both placenta and fetus without operative assistance. The
induction abortion interval will be defined as time from administration of 1st dose of
Misoprostol to abortion of fetus. Hemorrhage will be defined as an estimated blood loss
exceeding 500 ml or need to blood transfusion. Fever will be defined as rise of temperature
100.4˚ F or more occurring 24 hours or more after pregnancy termination.
The following parameters will be studied (1) Induction abortion interval (2) Completeness of
procedure (3) Failure of abortion (4) side effects (5) cost per procedure.
Statistical analysis will be carried out with Epi Info statistical software.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02208596 -
The Feasibility of Different Doses of Etomidate Admixed With Propofol in Induced Abortion: A Randomized, Double Blind Controlled Trial
|
Phase 4 | |
Completed |
NCT02412618 -
Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation
|
Phase 4 | |
Completed |
NCT01842100 -
To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy
|
N/A | |
Completed |
NCT00540748 -
Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful?
|
N/A | |
Completed |
NCT03727308 -
Study of Clinic-based Versus Self-use of Medical Abortion Pills
|
||
Completed |
NCT00482209 -
Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation
|
N/A | |
Recruiting |
NCT04242212 -
Study of Clinic-based vs. Self-use of a Misoprostol-only Regimen for Induced Abortion
|
||
Completed |
NCT00621543 -
Insertion of an Intrauterine Device (IUD) After Medical Abortion
|
N/A | |
Recruiting |
NCT01636063 -
Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks
|
N/A | |
Completed |
NCT01173003 -
Expansion Study of a Simplified Regimen of Medical Abortion Thru 63 Last Menstrual Period (LMP) in Tunisia
|
N/A | |
Completed |
NCT05532085 -
Assessment of Pain During an Abortion With Knowledge of the Predictive Factors of Pain.
|
||
Terminated |
NCT01776957 -
Post Abortion IUD & Recurrent Abortion 2005-2006
|
||
Completed |
NCT01047748 -
A Trial of Digoxin Before Second-Trimester Abortion
|
N/A | |
Completed |
NCT00619658 -
The Feasibility of Simplified Telephone Follow-up After Medical Abortion
|
N/A | |
Completed |
NCT00324519 -
Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester
|
Phase 4 | |
Completed |
NCT04181541 -
Midlevel Versus Physician-provided Medical Abortion in the Second Trimester
|
N/A | |
Completed |
NCT00286208 -
Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation
|
N/A | |
Completed |
NCT01085825 -
Study of the Sensitivity of Manual vs Electric Aspiration to Detect Completed Early Abortion
|
N/A |